Clinical trials: Atopic Eczema
Atopic Dermatitis
A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
The purpose of this study is to evaluate the safety, tolerability and the pharmacokinetics (PK) of topical ruxolitinib cream applied to pediatric subjects (age ≥ 2 to 17 years) with atopic dermatitis (AD).
- Trial name
- NCT03257644
- Testing
- Ruxolitinib phosphate cream
- Where
- 23 sites in United States
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
Dermatitis Atopic
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)
Primary Objective: To explore associations between biomarkers of atopic dermatitis (AD) and: Disease state and time course of AD, Disease state and evolution of selected atopic comorbid conditions, Effectiveness of specific AD…
- Trial name
- NCT03849716
- Testing
- Blood sample, Cheek swab
- Where
- 48 sites in United States, Argentina and 7 more
- Volunteers
- 266 people
- Sponsor
- Sanofi
Atopic Dermatitis, Eczema
Efficacy of Marine By-product Hydrolysate on the Reduction of Atopic Dermatitis Symptoms
This interventional, double-blind, randomized, placebo-controlled study aims to evaluate the effect of a marine by-product hydrolysate supplementation on the reduction of atopic dermatitis symptoms.
- Trial name
- NCT06268847
- Testing
- ACT01, ACT02
- Where
- Spain
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Abyss Ingredients
Moderate to Severe Atopic Dermatitis
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
The purpose of this study is to evaluate the study drug, SYX-5219, in a multi-part First-in-Human (FiH) study to be conducted in healthy volunteers and participants with Atopic Dermatitis (AD).
- Trial name
- NCT07558668
- Testing
- SYX-5219 Oral Capsule
- Where
- 14 sites in United States, Bulgaria and 4 more
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Sitryx Therapeutics Ltd
Atopic Dermatitis
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT07220577
- Testing
- GIA632
- Where
- 28 sites in United States, Bulgaria and 7 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis
The purpose of this study is to evaluate the Safety and Efficacy of FB825 in Adults with Atopic Dermatitis
- Trial name
- NCT03758716
- Testing
- FB825, FB825-15D11, Anti-CemX
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- Fountain Biopharma Inc.
Atopic Dermatitis
Topical Application of AS101 for the Treatment of Atopic Dermatitis
Atopic Dermatitis is a chronic non contagious disease that causes itchy, inflamed skin. The purpose of this study is to evaluate the safety and efficacy of topical AS101 ointment for the treatment of Atopic dermatitis.
- Trial name
- NCT00927212
- Testing
- AS101 ointment
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- BioMAS Ltd
Atopic Dermatitis (AD)
MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic Dermatitis
This is a Phase I/II Study of MH004 in Healthy Adult Volunteers, participants with Mild to Moderate Atopic Dermatitis.
- Trial name
- NCT07182864
- Testing
- MH004 0.1% Ointment, MH004 0.3% Ointment, MH004 1.0% Ointment
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Moderate-to-Severe Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07502222
- Testing
- AK139
- Volunteers
- 168 people
- Sponsor
- Akeso
Atopic Dermatitis
Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects
This study is not being conducted in the United States. To investigate the relative efficacy of pimecrolimus cream 1% applied twice daily (b.i.d.) versus once daily (o.d.) in preventing the progression to disease "relapse".
- Trial name
- NCT00139581
- Testing
- Pimecrolimus
- Where
- Switzerland
- Sponsor
- Novartis
Dermatitis, Dermatitis, Atopic
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
B7451029 is a Phase 3 study to investigate PF-04965842 in adult patients who have moderate to severe atopic dermatitis and use background topical therapy.
- Conditions
- Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases
- Trial name
- JADE Compare (NCT03720470)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab
- Where
- 216 sites in United States, Australia and 16 more
- Volunteers
- 838 people
- Sponsor
- Pfizer
Atopic Dermatitis, Eczema
A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
The purpose of this study is to learn about the safety and effects of Abrocitinib in the real-life clinical setting given for the treatment of moderate to severe atopic dermatitis.
- Trial name
- ADAIR (NCT05689151)
- Testing
- Abrocitinib
- Where
- 30 sites in France
- Volunteers
- 183 people
- Sponsor
- Pfizer
Atopic Dermatitis
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
This is a first-in-human, randomized, double-blind, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, tolerability, and PK of ATI-1777 solution following twice-daily applications to target areas of…
- Trial name
- NCT04598269
- Testing
- ATI-1777, Vehicle
- Where
- 14 sites in United States
- Volunteers
- 50 people
- Sponsor
- Aclaris Therapeutics, Inc.
Atopic Dermatitis of Adults
A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis
This study is ongoing to explore the efficacy and safety of different strengths of RSS0393 ointment in adults with atopic dermatitis
- Trial name
- NCT07158151
- Testing
- RSS0393 ointment
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Reistone Biopharma Company Limited
Atopic Dermatitis
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis
- Trial name
- NCT02595073
- Testing
- DSXS
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Atopic Dermatitis, Skin Diseases
Effect of Lipikar Baume AP+M on Quality of Life and Pain of Adults With Dryness or Severe Xerosis
This study aims at evaluating the effect of a topical product on the improvement of quality of life and pain of patients suffering from atopic dermatitis or other skin diseases with dryness or severe xerosis.
- Trial name
- NCT05765461
- Where
- 7 sites in Croatia, Germany and 5 more
- Volunteers
- 4,631 people
- Sponsor
- Cosmetique Active International
Atopic Dermatitis
A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India
The purpose of this clinical trial is to learn about the safety and how well the study medicine (called Abrocitinib) works for the potential treatment of moderate to severe Atopic Dermatitis (AD) in India.
- Trial name
- NCT05375929
- Testing
- Abrocitinib 100 mg, Abrocitinib 200 mg
- Where
- 15 sites in India
- Volunteers
- 200 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
The primary objective of this Phase 2 study is to evaluate the efficacy and safety of IBI3002 in patients with moderate to severe Atopic Dermatitis (AD).
- Trial name
- NCT07399067
- Testing
- IBI3002, Dupilumab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Eczema, Atopic
The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema
This is a double blind, randomised, non-clinical study with 2 groups (1 investigational group and 1 comparator group) aiming to assess the effectiveness of PEA for reducing eczema severity compared to a base comparator…
- Trial name
- NCT05003453
- Testing
- 1.5% Palmitoylethanolamide (PEA) sold as Levagen+
- Where
- Australia
- Volunteers
- 72 people
- Sponsor
- RDC Clinical Pty Ltd
Atopic Dermatitis
A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis
This is a Phase II, randomized, double-blind, placebo-controlled multicenter study of repeated doses of MOR106 administered as IV infusion.
- Trial name
- IGUANA (NCT03568071)
- Testing
- MOR 106
- Where
- 53 sites in Germany, Hungary and 3 more
- Volunteers
- 207 people
- Sponsor
- Lakefront Biotherapeutics NV